REG - Destiny Pharma PLC - Grant of Share Options
20/10/2023 07:00
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231020:nRST7233Qa&default-theme=true
RNS Number : 7233Q Destiny Pharma PLC 20 October 2023
Destiny Pharma plc
("Destiny Pharma" or the "Company")
Grant of Share Options
Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology
company focused on the development and commercialisation of novel medicines
that can prevent life-threatening infections, announces that it has granted
options over a total of 3,053,532 new ordinary shares of £0.01 each in the
Company ("Options") (representing 3.21 per cent. of the Company's issued share
capital) to the below named Directors of the Company.
Name Position Performance Options issued Total Options Options Ordinary Shares held Ordinary Shares held as a percentage
Under 2020 LTIP held held as a percentage of issued share capital of issued share capital
Scheme post issue
Chris Tovey Chief Executive Officer 2,453,532 2,453,532 2.58% 40,000* 0.04%
Shaun Claydon Chief Financial Officer 300,000 1,211,001 1.27% 24,286 0.03%
William Love Chief Scientific Officer 300,000 1,259,549 1.32% 6,509,500** 6.83%
*10,000 of these Ordinary Shares are held by Chris Tovey and 30,000 are held
by Chris Tovey's wife and two daughters
**1,017,700 of these Ordinary Shares are held by William Love and 5,491,800
are held by Carol Love
The above Options granted to the Directors represent awards under the Destiny
Pharma plc 2020 Long Term Incentive Plan approved by the Company on 22
December 2020 for EMI and non-tax advantaged options (the "Employee LTIP
2020"). The Options, which represent awards to Shaun Claydon and William Love
in relation to the year ended 31 December 2022 and to Chris Tovey pursuant to
an agreed equity incentive award on joining the Company, have been granted
with a nominal exercise price and will vest subject to the achievement of
Total Shareholder Return targets over a three-year performance period.
Following the grant of these Options, the Company will have in issue
outstanding options representing approximately 11.3 per cent. of its issued
share capital.
The Total Shareholder Return metrics will be fully laid out in the Company's
report and accounts for the year to 31 December 2023.
For further information, please contact:
Destiny Pharma plc
Chris Tovey, CEO
Shaun Claydon, CFO
+44 (0) 127 370 4440
pressoffice@destinypharma.com (mailto:pressoffice@destinypharma.com)
Cavendish Capital Markets Limited (Nominated Adviser and Joint Broker)
Geoff Nash / George Dollemore, Corporate Finance
Nigel Birks / Harriet Ward, ECM
+44 (0) 207 220 0500
Shore Capital (Joint Broker)
Daniel Bush / James Thomas / Lucy Bowden
+44 (0) 207 408 4090
Powerscourt Group
Sarah Macleod / Adam Michael / Ollie Simmonds / Christopher Ward
+44 (0) 20 7250 1446
Destiny@powerscourt-group.com (mailto:Destiny@powerscourt-group.com)
About Destiny Pharma
Destiny Pharma is an innovative, clinical-stage biotechnology company focused
on the development and commercialisation of novel medicines that can prevent
life-threatening infections. The company's drug development pipeline includes
two late stage assets NTCD-M3, a microbiome-based biotherapeutic for the
prevention of C. difficile infection (CDI) recurrence which is the leading
cause of hospital acquired infection in the US, and XF-73 nasal gel, a
proprietary drug targeting the prevention of post-surgical staphylococcal
hospital infections including MRSA.
For further information on the Company, please visit www.destinypharma.com
(https://url.avanan.click/v2/___http:/www.destinypharma.com___.YXAxZTpzaG9yZWNhcDphOm86MTUzZTZjNTdkOGU2YTA4YmVjZDAzYzcwMmJmODM0ODk6NjozZThjOjBmMDE5MWJiMjJkOWNlOGRjY2RlMzE3MGMzNGEwZDBjMDJlMmMwNmI3ZmMzYjZiMWY3MjM4MDA2N2ZjM2Y5YTE6cDpU)
This announcement contains inside information for the purposes of Article 7 of
the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic
law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is
disclosed in accordance with the company's obligations under Article 17 of MAR
Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them
1. Details of the person discharging managerial responsibilities / person closely
associated
a) Name Chris Tovey
2. Reason for the Notification
a) Position/status Chief Executive Officer
b) Initial notification/Amendment Initial notification
3. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Destiny Pharma plc
b) LEI 213800O9WH9Z38EHAC95
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the Financial instrument, type of instrument Options over ordinary shares of 1 pence each ("Ordinary Shares") under the
2020 Destiny Pharma plc Long Term Incentive Plan.
Identification code DEST GB00BDHSP575
b) Nature of the transaction Grant of options over Ordinary Shares under the 2020 Destiny Pharma plc Long
Term Incentive Plan.
c) Price(s) and volume(s) 1 pence exercise price per Ordinary Share
2,453,532 Ordinary Shares
d) Aggregated information:
Aggregated volume See 4c) above
Price
e) Date of the transaction 18 October 2023
f) Place of the transaction Outside of trading venue
1. Details of the person discharging managerial responsibilities / person closely
associated
a) Name Shaun Claydon
2. Reason for the Notification
a) Position/status Chief Financial Officer
b) Initial notification/Amendment Initial notification
3. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Destiny Pharma plc
b) LEI 213800O9WH9Z38EHAC95
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the Financial instrument, type of instrument Options over Ordinary Shares under the 2020 Destiny Pharma plc Long Term
Incentive Plan.
Identification code DEST GB00BDHSP575
b) Nature of the transaction Grant of options over Ordinary Shares under the 2020 Destiny Pharma plc Long
Term Incentive Plan.
c) Price(s) and volume(s) 1 pence exercise price per Ordinary Share
300,000 Ordinary Shares
d) Aggregated information:
Aggregated volume See 4c) above
Price
e) Date of the transaction 18 October 2023
f) Place of the transaction Outside of trading venue
1. Details of the person discharging managerial responsibilities / person closely
associated
a) Name William Love
2. Reason for the Notification
a) Position/status Chief Scientific Officer
b) Initial notification/Amendment Initial notification
3. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Destiny Pharma plc
b) LEI 213800O9WH9Z38EHAC95
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the Financial instrument, type of instrument Options over Ordinary Shares under the 2020 Destiny Pharma plc Long Term
Incentive Plan.
Identification code DEST GB00BDHSP575
b) Nature of the transaction Grant of options over Ordinary Shares under the 2020 Destiny Pharma plc Long
Term Incentive Plan.
c) Price(s) and volume(s) 1 pence exercise price per Ordinary Share
300,000 Ordinary Shares
d) Aggregated information:
Aggregated volume See 4c) above
Price
e) Date of the transaction 18 October 2023
f) Place of the transaction Outside of trading venue
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END DSHMLBFTMTMBBBJRecent news on Destiny Pharma
See all newsREG - Destiny Pharma PLC - Posting of Annual Report and Notice of AGM
AnnouncementREG - Destiny Pharma PLC - Full year results and review of strategic options
AnnouncementREG - Destiny Pharma PLC - Notice of Full Year Results
AnnouncementREG - Destiny Pharma PLC - Exercise of Options and Total Voting Rights
AnnouncementREG - Destiny Pharma PLC - Clinical development update
Announcement